• There are no suggestions because the search field is empty.

Careers    Developers    Support     日本語

Prostate Cancer
Trial Solutions

Enhancing study success with advanced clinical research technologies and expert solutions for Prostate Cancer trials.

DOWNLOAD BROCHURE GET IN TOUCH

Effective solutions for advancing Prostate Cancer research

Prostate cancer is the most common cancer among men, but it can be treated successfully. Signant Health applies decades of clinical experience and deep expertise with prostate cancer, as well as innovative clinical technologies within our Signant SmartSignals suite, to optimize the quality and reliability of data generated, helping teams identify new therapies sooner.

Prostate Cancer-1

Why Signant Health

  • Optimize PROM Reliability & Expedite Study Start-up
  • Capture More Robust Patient Function Data
  • Streamline Medication Management & Complex Cohorts
  • Reduce Burdens, Improve Convenience for Sites and Patients
  • Optimize PROM Reliability & Expedite Study Start-up

    Optimize PROM Reliability & Expedite Study Start-up

    Key endpoints in prostate cancer trials require reliable patient reported outcomes measurement (PROM) data. Our eCOA platform includes built-in, electronic, pre-validated PRO instruments to help patients provide complete, accurate, and timely responses, improving data accuracy compared to paper and pencil. 
     

  • Capture More Robust Patient Function Data

    Capture More Robust Patient Function Data

    Help your study team collect accurate data about treatment effects on patient function.  Our eCOA platform can integrate with sensors and wearables such as ActiGraph to automatically collect sleep and activity data without additional burden on patients or sites. Study teams can view this data alongside COA data for a more complete evaluation of patient function.
     
     

  • Streamline Medication Management & Complex Cohorts

    Streamline Medication Management & Complex Cohorts

    Prostate cancer studies often involve multiple patient cohorts and complex dosing schedules. Another variable adding complexity, investigational products for prostate cancer studies can be expensive as well as limited in supply and shelf life. Signant’s mature RTSM system ensures patients are randomized accurately and they receive the right medications at the right time and place. Mid-study changes can be implemented without disrupting study schedules. 

     

  • Reduce Burdens, Improve Convenience for Sites and Patients

    Reduce Burdens, Improve Convenience for Sites and Patients

    Oncology studies are complex and treatments carry risks that should be understood by well-informed patients. Signant’s eConsent solution improves comprehension and patient experience while providing sites with important version control features that ensure up-to-date informed consent forms. Our Telemedicine solution conveniently recreates the clinic experience when in-person visits aren't necessary.
     
     
     
     

Solutions informed by experience
0

STUDIES

0

PATIENTS

0

COUNTRIES

0

SITES

Explore Prostate Cancer trial optimization resources
SOLUTION BROCHURE

Prostate Cancer Trial Solutions Overview


GET INSIGHTS
INFOGRAPHIC

The Value of Patient-Reported Outcomes Data in Early-Phase Oncology Studies 




LEARN MORE
SOLUTION

Oncology Trial Solutions


 
EXPLORE FEATURES

eClinical solutions for Prostate Cancer trials

Ready to learn more?

Discover how Signant can support your current or upcoming prostate cancer trials. 

DOWNLOAD BROCHURE GET STARTED